Wh B, Mp S. Psoriasis. Lancet Lond Engl. 2015;386(9997). https://doi.org/10.1016/S0140-6736(14)61909-7

Leznoff AG, Sussman GL. Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients. J Allergy Clin Immunol. 1989;84(1). https://doi.org/10.1016/0091-6749(89)90180-2.

Atwa MA, Emara AS, Youssef N, Bayoumy NM. Serum concentration of IL-17, IL-23 and TNF-α among patients with chronic spontaneous urticaria: association with disease activity and autologous serum skin test. J Eur Acad Dermatol Venereol:JEADV. 2014;28(4). https://doi.org/10.1111/jdv.12124

Toubi E, Vadasz Z. The emerging role of IL-17 in the immune-pathogenesis of chronic spontaneous urticaria. ImmunoTargets Ther. 2020;9. https://doi.org/10.2147/ITT.S266410

Da S, et al. Interleukin-17 is a potential player and treatment target in severe chronic spontaneous urticaria. Clin Exp Allergy J Br Soc Allergy Clin Immunol. 2020;50(7). https://doi.org/10.1111/cea.13616.

Brzewski PŁ, et al. The role of focal infections in the pathogenesis of psoriasis and chronic urticaria. Postepy Dermatol Alergol. 2013;30(2). https://doi.org/10.5114/pdia.2013.34155

Karstarli Bakay OS, Kacar N. Combined treatment with omalizumab and secukinumab in a patient with chronic spontaneous urticaria and psoriasis. Dermatol Ther. 2022;35(9). https://doi.org/10.1111/dth.15638

Abdelmaksoud A, et al. Response of chronic refractory psoriasis vulgaris with urticaria to combined secukinumab and omalizumab: a case report and review of the literature. J Cosmet Dermatol. 2023;22(4). https://doi.org/10.1111/jocd.15551

Hoy SM. Deucravacitinib: first approval. Drugs. 2022;82(17):1671–9. https://doi.org/10.1007/s40265-022-01796-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chimalakonda A, et al. Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1/2/3 inhibitors. Dermatol Ther. 2021;11(5):1763–76. https://doi.org/10.1007/s13555-021-00596-8.

Article  Google Scholar 

Zhang J, et al. Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial. Br J Dermatol. 2025;192(3):402–9. https://doi.org/10.1093/bjd/ljae406.

Article  PubMed  Google Scholar 

Armstrong AW, et al. Deucravacitinib in plaque psoriasis: four-year safety and efficacy results from the phase 3 POETYK PSO-1, PSO-2 and long-term extension trials. J Eur Acad Dermatol Venereol JEADV. 2025. https://doi.org/10.1111/jdv.20553.

Article  PubMed  Google Scholar 

Rusiñol L, Puig L. Tyk2 targeting in immune-mediated inflammatory diseases. Int J Mol Sci. 2023;24(4):3391. https://doi.org/10.3390/ijms24043391.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Armstrong AW, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29–39. https://doi.org/10.1016/j.jaad.2022.07.002.

Article  CAS  PubMed  Google Scholar 

Ye D, et al. MRGPRX2 gain-of-function mutation drives enhanced mast cell reactivity in chronic spontaneous urticaria. J Allergy Clin Immunol. 2025; S0091–6749(25)00305–7. https://doi.org/10.1016/j.jaci.2025.03.007.

Asero R, Calzari P, Vaienti S, Cugno M. Therapies for chronic spontaneous urticaria: present and future developments. Pharm Basel Switz. 2024;17(11):1499. https://doi.org/10.3390/ph17111499.

Article  CAS  Google Scholar 

Strobl B, Stoiber D, Sexl V, Mueller M. Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity. Front Biosci Landmark Ed. 2011;16(9):3214–32. https://doi.org/10.2741/3908.

Article  PubMed  Google Scholar 

Bernstein JA, Maurer M, Saini SS. BTK signaling-a crucial link in the pathophysiology of chronic spontaneous urticaria. J Allergy Clin Immunol. 2024;153(5):1229–40. https://doi.org/10.1016/j.jaci.2023.12.008.

Article  PubMed  Google Scholar 

Yosipovitch G, Biazus Soares G, Mahmoud O. Current and emerging therapies for chronic spontaneous urticaria: a narrative review. Dermatol Ther. 2023;13(8):1647–60. https://doi.org/10.1007/s13555-023-00972-6.

Article  Google Scholar 

Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021;148(4):927–40. https://doi.org/10.1016/j.jaci.2021.08.009.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang I-H, Chung W-H, Wu P-C, Chen C-B. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review. Front Immunol. 2022;13: 1068260. https://doi.org/10.3389/fimmu.2022.1068260.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mansouri P, Mozafari N, Chalangari R, Martits‐Chalangari K. Efficacy of oral tofacitinib in refractory chronic spontaneous urticaria and urticarial vasculitis. Dermatol Ther. 2022;35(12):e15932. https://doi.org/10.1111/dth.15932